Table 1.
Compound | SI | SD |
---|---|---|
(+)‐Gallocatechin‐3‐gallate (GCG) | 1.0 | 1.1 |
Benzene‐1,2,3‐triol (pyrogallol) | 1.5 | 1.6 |
(−)‐Epigallocatechin‐3‐gallate (EGCG) | 1.6 | 0.6 |
Ursolic acid | 1.9 | 2.5 |
(+)‐Gallocatechin | 9.7 | 4.9 |
3,4,5‐Trihydroxybenzoic acid (gallic acid) | 34.0 | 19.1 |
5‐Fluorouracil | 39.0 | 10.8 |
(4R)‐5‐(3′,4′‐dihydroxyphenyl)‐γ‐valerolactone | 44.7 | 22.3 |
Benzene‐1,2‐diol (catechol or pyrocatechol) | 50.7 | 16.3 |
Naringenin | 54.7 | 6.3 |
Resveratrol | 55.6 | 27.7 |
Luteolin | 58.9 | 28.2 |
2′‐Hydroxycinnamic acid (o‐coumaric acid) | 63.8 | 36.5 |
3‐(3′,4′‐Dihydroxyphenyl)propanoic acid (dihydrocaffeic acid) | 65.2 | 14.7 |
3′,4′‐Dihydroxyphenylacetic acid | 67.6 | 18.8 |
5‐(3′,4′‐Dihydroxyphenyl)valeric acid | 68.7 | 7.9 |
Glycitein 7‐O‐glucoside (glycitin) | 76.1 | 10.1 |
4′‐Hydroxy‐3′‐methoxycinnamic acid (ferulic acid) | 80.1 | 13.4 |
3D HTC116 spheroids were treated at 50 µM from at least four independent experiments. After 72 h of exposure, the SI parameter was calculated as a percentage of the control (DMSO 0.05%).